FDA to Exempt Phase I Drugs From GMP Requirements

Clinical Trials Advisor
After withdrawing a final rule more than two years ago to exempt investigational drugs in Phase I testing from certain good manufacturing practice (GMP) regulations, the FDA is issuing another final rule that will do just that.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $10.00